DERMATA THERAPEUTICS, INC. Debt Instrument, Convertible, Conversion Price
DERMATA THERAPEUTICS, INC. (DRMA) had Debt Instrument, Convertible, Conversion Price of $0.80 per share as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionPrice1 · last filed 2022-11-10
- 2022-09-30: Debt Instrument, Convertible, Conversion Price $0.80.
- 2022-06-30: Debt Instrument, Convertible, Conversion Price $0.80.
- 2022-03-31: Debt Instrument, Convertible, Conversion Price $0.80.
- 2021-12-31: Debt Instrument, Convertible, Conversion Price $0.80.
| Period end | Debt Instrument, Convertible, Conversion Price |
|---|---|
| 2022-09-30 | $0.80 10-Q · filed 2022-11-10 |
| 2022-06-30 | $0.80 10-Q · filed 2022-08-15 |
| 2022-03-31 | $0.80 10-Q · filed 2022-05-16 |
| 2021-12-31 | $0.80 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |